Testing MRG-001 for people with ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ALS (definite, probable, or lab-supported probable) and symptoms started less than 4 years ago.
- Your lung function is at least 50% of what is expected for your age, height, and sex.
- If you take Riluzole, Edaravone, or Relyvrio, you have been on a stable dose (or not taken them) for at least 30 days before the study starts.
- You are willing to use effective birth control during the study (if you are of childbearing potential).
- You do not have serious heart, lung, kidney, or blood problems, and you have not had a splenectomy or an enlarged spleen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.